← FDA DRUG APPROVALS
FDA ANDA · ANDA210542
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Sponsor: ZYDUS PHARMS USA INC
APPLICATION
ANDA210542
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)
Products
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDENone (Tentative Approval)
CANAGLIFLOZIN 150MG, METFORMIN HYDROCHLORIDE 500MG · TABLET · ORAL
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDENone (Tentative Approval)
CANAGLIFLOZIN 50MG, METFORMIN HYDROCHLORIDE 500MG · TABLET · ORAL
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDENone (Tentative Approval)
CANAGLIFLOZIN 150MG, METFORMIN HYDROCHLORIDE 1000MG · TABLET · ORAL
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDENone (Tentative Approval)
CANAGLIFLOZIN 50MG, METFORMIN HYDROCHLORIDE 1000MG · TABLET · ORAL
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.